Quantcast

Latest Cachexia Stories

2010-12-27 07:02:00

MORRISTOWN, N.J., Dec. 27, 2010 /PRNewswire/ -- Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia. The randomized, open label, multi-center Phase 2 study will evaluate whether VT-122 in...

2010-06-06 07:00:00

CHICAGO, June 6 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that patients with late-stage non-small cell lung cancer (NSCLC) showed improvement in cancer-related anemia and symptoms of the disease in a Phase 2a clinical trial of ALD518, a monoclonal antibody directed against interleukin-6 (IL-6). After 12 weeks of treatment with the anti-inflammatory therapeutic, 58 percent of patients who received ALD518 experienced hemoglobin level increases from less than 11 g/dL to...

2009-12-14 04:30:00

DOVER, Del., Dec. 14 /PRNewswire/ --Ohr Pharmaceutical Inc. (OTC Bulletin Board: OHRP) announced today it has selected Allen & Caron Inc, headquartered in Irvine, CA, with offices also in New York and London, as its agency for investor relations and corporate communications. Ohr Pharmaceutical is a development stage biotechnology company focused on developing advanced drugs for underserved therapeutic needs. The Company acquired two pipeline compounds with potentially large, global...

2009-09-25 04:35:29

Insulin resistance, the hallmark of type 2 diabetes and a condition often associated with obesity, is paradoxically also an apparent contributor to muscle wasting and severe fat loss that accompanies some cancers, according to new research. And in an animal study, a diabetes drug that promotes insulin sensitivity slowed the progression of muscle wasting and fat loss, the main consequences of a syndrome called cachexia, in mice with colon cancer tumors. Though it remains unknown whether that...

061757dc483b5398a0443d0a235658011
2009-05-19 10:40:00

Experts say severe malnutrition and weight loss play a role in at least one in five cancer deaths and now American institutions are making changes to combat this, The Associated Press reported. Hospitals are now hiring highly trained gourmet chefs, while the American Cancer Society's dietitians-on-call phone service is working toward providing better food with better nutrition for cancer patients. Certified Master Chef Jack Shoop, who is in charge of the kitchen at the Cancer Treatment...

2009-01-23 19:20:31

A U.S. physician suggests doctors are not doing enough to pick up on problems associated with excessive weight loss -- a condition called cachexia. Dr. John Morley, an endocrinologist at Saint Louis University who helped draft recent guidelines to diagnose cachexia -- published in the medical journal Clinical Nutrition -- said weight loss in sick people is an important indicator of disease and potentially impending death. Cachexia is an extraordinary problem for people who are having other...

1133bcb4db54d77a860c9d0fbdfeee0c1
2009-01-21 16:28:28

Saint Louis University doctor helps draft new guidelines for wasting disease Doctors are not doing enough to pick up on problems with excessive weight loss, says a Saint Louis University physician who helped draft recent guidelines to diagnose the condition called "cachexia" (kuh-kex-ee-uh). "In sick people, weight loss is an important indicator of disease and potentially impending death," said John Morley, M.D., an endocrinologist and director of the division of geriatric medicine at Saint...

2008-10-16 06:00:10

Tranzyme Pharma, a biopharmaceutical company engaged in the discovery and clinical development of first-in-class small molecule therapeutics, announced that Dr. Helmut Thomas, Senior Vice President of Research and Preclinical Development will present results of a significant proof-of-concept study in cancer cachexia with its novel ghrelin agonist, TZP-101. The presentation will take place at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva,...

2008-10-14 03:00:12

GTx, a biopharmaceutical company, has announced positive topline results of a Phase II clinical trial evaluating Ostarine, an investigational selective androgen receptor modulator, in patients with cancer induced muscle loss, also known as cancer cachexia. In this analysis, the study met its primary endpoint of absolute change in total lean body mass (muscle) compared to placebo and the secondary endpoint of muscle function (performance) after 16 weeks of treatment. GTx plans to present...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related